Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal
women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Investigators are
looking to see if patients with joint pain see improvement with the use of CBD.